Add time:08/22/2019         Source:sciencedirect.com

In this study we attempted to develop Pluronic micelles delivering the photodynamic therapy photosensitizers benzoporphyrin derivatives (BPD). The BPD A-ring (BPDMA or Verteporfin®, the active drug of FDA/USA approved Visudyne®), its regioisomer ring-B (BPDMB, not used in Visudyne® formulation due its poor solubility) and a BPDMA/BPDMB mixture (BPD-Mixt) were formulated in Pluronic P123 or F127 as well as P123/F127 mixed micelles at two different mass ratios. P123/F127 presented the lowest critical micelle concentration showing high stability due synergistic aggregation of P123 and F127. Mixed micelles allowed the encapsulation of BPD as monomers enhancing their photophysical properties and stability during time even under diluted conditions. High loading was attributed to the strong hydrophobic affinity of BPD for micelle core especially in the binary system due synergistic aggregation of P123 and F127 demonstrating the high potential of these micelles to encapsulate hydrophobic drugs. The in vitro assays showed a photo-activity of BPD-Mixt comparable to that of BPDMA against HeLa and A549 cancer cells under red light. The use of BPD-mixed formulations avoids the complex separation steps of these regioisomers and implies in cost reduction. The proposed system allies costs reduction and photodynamic efficiency, which stimulates further development on this nanosystem and may be of clinical interest for cancer PDT.

We also recommend Trading Suppliers and Manufacturers of benzoporphyrin D (cas 113719-89-4). Pls Click Website Link as below: cas 113719-89-4 suppliers